Civil Litigation,
Intellectual Property
May 14, 2019
Another win for Sandoz; another nail in the coffin of the doctrine of equivalents
On May 8, in Amgen v. Sandoz, the U.S. Court of Appeals for the Federal Circuit handed the biosimilar giant another win in two related cases in the long-running legal battle that started in 2014, when Amgen brought the very first patent infringement case under the Biologics Price Competition and Innovation Act of 2009.
Limin Zheng
Partner
Miclean Gleason LLP
Email: lzheng@micleangleason.com
Limin's practice emphasizes patent and other complex technology litigation and spans a broad range of technologies, with a focus on biotechnology, biotherapeutics, and medical devices.
On May 8, in Amgen v. Sandoz, the U.S. Court of Appeals for the Federal Circuit handed the biosimilar giant another win in two related cases in the long-running legal battle that started in 2014, when Amgen brought the very first patent infringement case under the Biologics Price Competition and Innovation ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In